Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
VERACYTE, INC. director Karin Eastham reported selling 3,729 shares of common stock on June 18, 2026 in open-market transactions. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 5, 2025, at weighted average prices of $52.78 and $53.55 per share.
EASTHAM KARIN reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Karin Eastham received a grant of 5,272 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost and increase her direct holdings to 18,826 shares following the transaction.
The restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the grant date, or immediately before Veracyte’s next annual stockholder meeting if that occurs earlier. They also vest in full if there is a change in control of the company.
VERACYTE, INC. director Evan Jones received an equity award in the form of 5,272 shares of common stock on June 11, 2026, reported as a grant or other acquisition with no purchase price. Following this award, he directly holds 34,634 shares.
The award represents restricted stock units that vest in full on the first anniversary of the grant date or immediately before the company’s next annual stockholder meeting, whichever occurs first. The units also vest in full if there is a change in control of the issuer.
Shafer David Brent reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director David Brent Shafer received a grant of 5,272 restricted stock units on June 11, 2026 as equity compensation. These units vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, if earlier, and also fully vest upon a change in control. Following this award, Shafer directly holds 31,100 shares of Veracyte common stock.
Barr Eliav reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Eliav Barr received a grant of 5,272 shares of common stock in the form of restricted stock units. These RSUs were awarded on June 11, 2026 and increase his direct holdings to 56,461 shares. The units vest in full on the first anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, whichever comes first. They also vest in full if there is a change in control of the company.
EPSTEIN ROBERT S reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Robert S. Epstein received an equity award in the form of 5,272 shares of common stock on June 11, 2026. The grant was made at a price of $0.00 per share as compensation rather than an open-market purchase. Following this award, Epstein directly holds 57,718 shares of Veracyte common stock. The underlying restricted stock units vest in full on the first anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders, if earlier, and they also vest in full upon a change in control of the issuer.
Holstein Jens reported acquisition or exercise transactions in this Form 4 filing.
Veracyte director Jens Holstein received an equity grant of 5,272 shares of Common Stock on June 11, 2026. The award is in the form of restricted stock units that vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, if earlier.
The restricted stock units also vest in full if there is a change in control of Veracyte. After this grant, Holstein directly holds 32,471 shares of Veracyte common stock.
Bhanji Muna reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Muna Bhanji received an equity award in the form of 5,272 shares of common stock on June 11, 2026, granted at no cash cost as a restricted stock unit award. Following the grant, Bhanji directly holds 44,582 shares. The restricted stock units vest in full on the first anniversary of the grant date or immediately before Veracyte’s next annual stockholder meeting, whichever comes first, and they also vest in full if there is a change in control of the company.
Miller Thomas F. reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Thomas F. Miller received a grant of 5,272 shares of common stock in the form of restricted stock units on June 11, 2026. These units vest in full on the first anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, whichever comes first, and also vest in full upon a change in control of the issuer. Following this award, Miller directly holds 31,100 shares of Veracyte common stock.